Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA)’s stock price has gone rise by 0.82 in comparison to its previous close of 18.39, however, the company has experienced a -6.97% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-13 that – ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 – $580 million – – Kiniksa expects to remain cash flow positive on an annual basis –
Is It Worth Investing in Kiniksa Pharmaceuticals International Plc (NASDAQ: KNSA) Right Now?
The stock has a 36-month beta value of 0.32. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KNSA is 39.73M, and at present, short sellers hold a 8.53% of that float. On January 20, 2025, the average trading volume of KNSA was 359.12K shares.
KNSA’s Market Performance
KNSA’s stock has seen a -6.97% decrease for the week, with a -8.76% drop in the past month and a -29.56% fall in the past quarter. The volatility ratio for the week is 4.25%, and the volatility levels for the past 30 days are at 3.31% for Kiniksa Pharmaceuticals International Plc The simple moving average for the past 20 days is -5.79% for KNSA’s stock, with a -15.23% simple moving average for the past 200 days.
Analysts’ Opinion of KNSA
Many brokerage firms have already submitted their reports for KNSA stocks, with Jefferies repeating the rating for KNSA by listing it as a “Buy.” The predicted price for KNSA in the upcoming period, according to Jefferies is $40 based on the research report published on September 13, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see KNSA reach a price target of $34. The rating they have provided for KNSA stocks is “Overweight” according to the report published on May 03rd, 2024.
BofA Securities gave a rating of “Buy” to KNSA, setting the target price at $40 in the report published on June 29th of the previous year.
KNSA Trading at -11.05% from the 50-Day Moving Average
After a stumble in the market that brought KNSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.14% of loss for the given period.
Volatility was left at 3.31%, however, over the last 30 days, the volatility rate increased by 4.25%, as shares sank -9.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.69% lower at present.
During the last 5 trading sessions, KNSA fell by -6.97%, which changed the moving average for the period of 200-days by -1.01% in comparison to the 20-day moving average, which settled at $19.68. In addition, Kiniksa Pharmaceuticals International Plc saw -6.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KNSA starting from Tessari Eben, who sale 14,000 shares at the price of $18.24 back on Jan 13 ’25. After this action, Tessari Eben now owns 88,975 shares of Kiniksa Pharmaceuticals International Plc, valued at $255,413 using the latest closing price.
Tessari Eben, the Officer of Kiniksa Pharmaceuticals International Plc, proposed sale 14,000 shares at $18.24 during a trade that took place back on Jan 13 ’25, which means that Tessari Eben is holding shares at $255,390 based on the most recent closing price.
Stock Fundamentals for KNSA
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.61 for the gross margin
The net margin for Kiniksa Pharmaceuticals International Plc stands at -0.02. The total capital return value is set at -0.06. Equity return is now at value -2.15, with -1.75 for asset returns.
Based on Kiniksa Pharmaceuticals International Plc (KNSA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 1.06. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -14.32.
Currently, EBITDA for the company is -22.86 million with net debt to EBITDA at 3.46. When we switch over and look at the enterprise to sales, we see a ratio of 3.26. The receivables turnover for the company is 15.43for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
To sum up, Kiniksa Pharmaceuticals International Plc (KNSA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
